Fine characterization of mitral valve glycosaminoglycans and their modification with degenerative disease

Luca Dainese1, Gianluca Polvani, Fabio Barili

  • 1Department of Cardiac and Vascular Surgery, Centro Cardiologico Monzino, IRCCS University of Milan, Milan, Italy.

Abstract

Insights

Glycosaminoglycan (GAG) composition in mitral valve leaflets changes with mitral regurgitation, showing more hyaluronic acid and less sulfated GAGs. These alterations may weaken the tissue and affect its mechanical properties.

Area of Science:

  • Biochemistry
  • Cardiovascular Biology
  • Tissue Engineering

Background:

  • Investigated glycosaminoglycan (GAG) levels and structure in posterior mitral valve leaflets (MVL).
  • Compared MVL tissue from patients with mitral regurgitation and degenerative disease to healthy controls.

Purpose of the Study:

  • To determine the fine structure and levels of complex polysaccharides (GAGs) in MVL.
  • To compare GAG composition between diseased and healthy mitral valve tissue.

Main Methods:

  • Analyzed MVL GAGs using agarose gel electrophoresis.
  • Employed HPLC and fluorophore-assisted carbohydrate electrophoresis for disaccharide pattern analysis after chondroitinase ABC treatment.

Main Results:

  • Control MVL GAGs comprised 37% hyaluronic acid and 63% chondroitin sulfate/dermatan sulfate.
  • Diseased MVL showed significantly higher hyaluronic acid (+38%) and lower sulfated GAGs (-21%), decreasing charge density by 23%.
  • Alterations included a decrease in 4-sulfated disaccharides within sulfated polysaccharides.

Conclusions:

  • Changes in GAG composition in mitral regurgitation suggest reduced tissue tension.
  • Abnormal matrix microstructure may influence hydration and mechanical weakness in pathological MVL.
  • Altered GAGs contribute to the mechanical dysfunction observed in mitral valve disease.

Related Concept Videos

Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Proteoglycans01:05

Proteoglycans

Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...